secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atrium Therapeutics, Inc. (RNA)
CIK:        0002093101
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-083227
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atrium Therapeutics completes spin-off from Avidity; begins trading under RNA on Nasdaq
--------------------------------------------------------------------------------

- Separation of Atrium Therapeutics (SpinCo) from Avidity effective Feb 26, 2026; one SpinCo share for every ten Avidity shares distributed.
- Amended License Agreement expands IP cross-licenses; Transition Services Agreement provides support services from Avidity.
- Board elected: Carsten Boess, W. Michael Flanagan, Simona Skerjanec, Troy Wilson; terms expire at first/second annual meetings.
- Executive officers: Kathleen Gallagher (CEO) and Brendan Winslow (CFO); employment agreements and compensatory plans adopted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/d87849d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-083227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer